Home
About
Overview
Sharing Data
ORCID
Help
History (7)
Phase I dose-escalation study of onartuzumab as a single agent and in combination with bevacizumab in patients with advanced solid malignancies.
Sex differences in proximal and distal nephron function contribute to the mechanism of idiopathic hypercalcuria in calcium stone formers.
Shah, Nick
The Longer-Term Benefits and Harms of Glucagon-Like Peptide-1 Receptor Agonists: a Systematic Review and Meta-Analysis.
Biopsy-free circulating tumor DNA assay identifies actionable mutations in lung cancer.
See All 7 Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Biopsy-free circulating tumor DNA assay identifies actionable mutations in lung cancer.
Biopsy-free circulating tumor DNA assay identifies actionable mutations in lung cancer. Oncotarget. 2016 Oct 11; 7(41):66880-66891.
View in:
PubMed
subject areas
Adolescent
Adult
Aged
Aged, 80 and over
Biomarkers, Tumor
Carcinoma, Non-Small-Cell Lung
Circulating Tumor DNA
Disease-Free Survival
DNA, Neoplasm
ErbB Receptors
Female
High-Throughput Nucleotide Sequencing
Humans
Liquid Biopsy
Lung
Lung Neoplasms
Male
Middle Aged
Mutation
Neoplastic Cells, Circulating
Young Adult
authors with profiles
Ravi Salgia